Global Attention Deficit Hyperactivity Disorder Treatment: Key Developments
In September 19, 2022, Cingulate, a biopharmaceutical company that focused on the development of new product candidates for the treatment of central nervous system and neurobiological disorders, presents data for its product candidate called CTx-2103, an extended release tablet of busporin used for treatment of anxiety related disease like attention deficit hyperactivity disorder in children as well as adults.
In July 2021, Adlon Treatment L.P., a subsidiary of Purdue Pharma L.P., a specialty pharmaceutical company committed to provide treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD), announced the approval of supplement new drug application for ADHANSIA XR(methylphenidate HCI) extended release capsules CII for treatment of ADHD. ADHANSIA XR capsule contains multilayered beads, composed of immediate release layer and 20 percent of methylphenidate dose.
Attention Deficit Hyperactivity Disorder Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients